SNORD65: A Key Regulator of The TGF-β Pipeline (G692106)

Target Name: SNORD65

NCBI ID: G692106

SNORD65

Other Name(s): SNORD65A | HBII-135 | Small nucleolar RNA, C/D box 65 | small nucleolar RNA, C/D box 65

SNORD65: A Key Regulator of The TGF-β Pipeline

SNORD65 (SNORD65A) is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a key regulator of the cell signaling pathway known as the TGF-β pathway, which plays a crucial role in the development, maintenance, and regression of tissues and organs.

The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. It is composed of several transcription factors, including SMAD1, SMAD4, TGF-β1, and TGF-β2. These transcription factors bind to specific DNA sequences to regulate the expression of target genes.

SNORD65 is a key regulator of the TGF-β pathway. It is a protein that contains several domains, including a N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal TGF-β-responsive element. The N-terminal transmembrane domain is responsible for the protein's ability to interact with the TGF-β receptor, while the coiled-coil domain is responsible for the protein's ability to undergo conformational changes that regulate its activity.

SNORD65 is highly expressed in various tissues and organs, including the brain, heart, and kidneys. It is also expressed in various cell types, including neurons, astrocytes, and endothelial cells. In the brain, SNORD65 is expressed in the postsynaptic density protein (PSP) neurons, which are responsible for transmitting signals from other neurons and glial cells.

SNORD65 is involved in the regulation of several cellular processes, including cell growth, differentiation, and survival. It is a key regulator of the TGF-β pathway, which is involved in the regulation of cell growth, differentiation, and survival. SNORD65 is also involved in the regulation of cell-cell adhesion, as it is expressed in the tight junction protein (TJP) channels that mediate cell-cell adhesion.

SNORD65 is a potential drug target for several diseases. Its involvement in the TGF-β pathway makes it a potential target for therapies that are aimed at modulating cell growth, differentiation, and survival. For example, SNORD65 has been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the regulation of cancer, and has been shown to be involved in the regulation of several types of cancer, including breast, lung, and colorectal cancer.

SNORD65 is also a potential biomarker for several diseases. Its involvement in the TGF-β pathway makes it a potential target for biomarkers that are aimed at identifying therapies that are effective in modulating cell growth, differentiation, and survival. For example, SNORD65 has been shown to be involved in the regulation of fibrosis, and has been shown to be involved in the regulation of several types of fibrosis, including renal and liver fibrosis.

In conclusion, SNORD65 is a protein that is expressed in various tissues and organs, including the brain, heart, and kidneys. It is a key regulator of the cell signaling pathway known as the TGF-β pathway, and is involved in the regulation of cell growth, differentiation, and survival. As a potential drug target and biomarker, SNORD65 is a promising target for the development of new therapies aimed at modulating cell behavior and function.

Protein Name: Small Nucleolar RNA, C/D Box 65

The "SNORD65 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD65 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets